Matthew J. Budoff, MD

In the final episode, ‘Risk-Based Management in Hypercortisolism,’ the panelists explored how to approach hypercortisolism management in the absence of widely accessible, targeted therapies, emphasizing a risk-based treatment paradigm.

In ‘Emerging Therapies in Hypercortisolism,’ our panel explores the evolving therapeutic landscape for hypercortisolism and the future direction of treatment development.

In this episode, ‘Hypercortisolism and Cardiovascular Risk Management,’ the panelists explore the broader implications of hypercortisolism on cardiovascular risk and the role of cardiologists in comprehensive patient management.

This episode, titled ‘Hypercortisolism Treatment and Care Pathways,’ features panelists discussing the management of hypercortisolism following diagnosis, with a focus on the roles of cardiologists and endocrinologists in coordinating care.

In ‘Hypertension Management in Hypercortisolism,’our panel explores the clinical implications of emerging data on hypercortisolism and outline a forward-looking approach to hypertension management.

In this episode, ‘Hypercortisolism and Guideline Implications,’ the panelists explore the implications of emerging hypercortisolism data for clinical guidelines and routine cardiovascular practice.

This episode, titled ‘Recognizing Hypercortisolism in Cardiology,’ features panelists discuss the clinical implications of emerging hypercortisolism data for cardiologists and how these findings should influence everyday practice.

In ‘Hypercortisolism Hidden in Resistant Hypertension,’ our panel explored the design, findings, and clinical implications of the MOMENTUM study, a large, multicenter trial evaluating the prevalence of hypercortisolism in patients with resistant hypertension.

In this episode, ‘Hypercortisolism and Difficult to Control Diabetes,’ the panelists explore the relationship between hypercortisolism and difficult-to-control diabetes, highlighting the role of excess cortisol as a key driver of metabolic dysfunction.

This episode, titled ‘Hypercortisolism in Resistant Diabetes and Cardiometabolic Disease,’ features panelists expanding the discussion of hypercortisolism beyond hypertension to include patients with poorly controlled or “resistant” diabetes, highlighting another high-risk population where cortisol excess may be underrecognized.

In ‘Evolving Hypercortisolism Screening and Diagnosis,’ our panel explored how emerging evidence is reshaping the approach to screening and diagnosing hypercortisolism in cardiovascular practice.

This episode explores how hypercortisolism extends beyond classic Cushingoid features, highlighting its variable presentation and role as a continuum of cortisol-driven cardiometabolic disease that is often underrecognized in clinical practice.

The panel discusses how hypercortisolism presents variably beyond classic Cushingoid features, emphasizing it as a spectrum of metabolic dysfunction with serious cardiovascular and systemic impacts.

Budoff suggests monitoring serum lipoproteins like Lp(a) and ApoB to predict cardiovascular disease risk in patients with no conventional indicators.

Matthew J. Budoff, MD discusses the effects of obesity and cardiometabolic complications in the contemporary management of type 1 diabetes.

Drs Paul S. Jellinger, Erin D. Michos, Matthew J. Budoff, Christie Ballantyne, and Yehuda Handelsman share closing thoughts and advice for the management of ASCVD and hypercholesterolemia.

Experts in endocrinology and cardiology review novel agents in the pipeline for the management of hypercholesterolemia and ASCVD.

Erin D. Michos, MD, MHS, leads a discussion on selecting the appropriate patient populations for the use of bempedoic acid when managing atherosclerotic cardiovascular disease (ASCVD) and hypercholesterolemia.

Christie Ballantyne, MD, leads a discussion on the use of bempedoic acid for the management of atherosclerotic cardiovascular disease (ASCVD) and hypercholesterolemia as seen in the CLEAR studies.

Erin D. Michos, MD, MHS; Christie Ballantyne, MD; Yehuda Handelsman, MD; and Paul S. Jellinger, MD, MACE, address the use of combination therapies and statin intolerance in patients with atherosclerotic cardiovascular disease (ASCVD) and hypercholesterolemia.

Matthew J. Budoff, MD; Paul S. Jellinger, MD, MACE; Erin D. Michos, MD, MHS; Yehuda Handelsman, MD; and Christie Ballantyne, MD, comment on the use of icosapent ethyl in reducing atherosclerotic cardiovascular disease (ASCVD) events and managing lipid disorders.

Health care experts discuss use of older agents to control atherosclerotic cardiovascular disease (ASCVD) and hypercholesterolemia in certain patient populations.

Christie Ballantyne, MD, leads a discussion on the efficacy and safety of bempedoic acid for the management of ASCVD and hypercholesterolemia.

Matthew J. Budoff, MD; Erin D. Michos, MD, MHS; and Paul S. Jellinger, MD, MACE, discuss the role of statins, ezetimibe, and PSCK9 inhibitors for patients with ASCVD and hypercholesterolemia.

Christie Ballantyne, MD, and Erin D. Michos, MD, MHS, explore the impact of lifestyle changes on managing ASCVD and hypercholesterolemia.

Expert endocrinologists and cardiologists review the role of DCRM multispecialty practice recommendations and the use of combination therapy for patients with ASCVD and hypercholesterolemia.

Drs Erin D. Michos, Matthew J. Budoff, Paul S. Jellinger, and Yehuda Handelsman, share their approach to incorporating guideline recommendations for the management of patients with ASCVD and hypercholesterolemia in clinical practice.

Dr Christie Ballantyne leads a discussion on how the management of patients with ASCVD and hypercholesterolemia has changed over the years.

Yehuda Handelsman, MD; Christie Ballantyne, MD; Paul S. Jellinger, MD, MACE; and Erin D. Michos, MD, MHS, comment on the impact of diabetes on chronic kidney disease and cardiovascular disease.

Matthew J. Budoff, MD; Christie Ballantyne, MD; and Paul S. Jellinger, MD, MACE, discuss the incidence and prevalence of atherosclerotic cardiovascular diseases (ASCVD) associated with hypercholesterolemia and risk factors for disease.